42C.SI - iX Biopharma Ltd.

SES - SES Delayed Price. Currency in SGD
-0.0100 (-4.55%)
At close: 11:55AM SGT
Stock chart is not supported by your current browser
Previous Close0.2200
Bid0.2100 x 0
Ask0.2200 x 0
Day's Range0.2100 - 0.2100
52 Week Range0.1600 - 0.2850
Avg. Volume113,557
Market Cap135.365M
Beta (3Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.0050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.43
  • PR Newswire

    First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA

    SINGAPORE, May 21, 2019 /PRNewswire/ -- iX Biopharma Ltd (42C.SI) announced today that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration (FDA) has scheduled the End-of-Phase 2 (EOP2) meeting with the Company in the third quarter of 2019. The results of the Phase 2b randomized, double-blind, placebo-controlled study on Wafermine demonstrated strong analgesic efficacy, safety and tolerability in participants experiencing moderate to severe acute, post-operative pain after undergoing either abdominoplasty or bunionectomy surgery.

  • We're sorry this is all we were able to find about this topic.